Leslie M Randall1, Bradley J Monk. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Building 56 Room 264, 101 The City Dr., Orange CA 92868, USA. lrandall@uci.edu
Abstract
OBJECTIVES: The purpose of this review is to discuss the side effect profile of bevacizumab, to discuss proposed mechanisms of these toxicities, and to provide suggestions for management of adverse events. METHODS: A search of MEDLINE and ASCO and SGO abstract databases of articles published between January 1970 and August 2009 addressing the toxicity of bevacizumab in solid tumors was conducted. Reporting was limited to best available evidence including any available phase III studies and ovarian cancer phase II studies. Original publications addressing underlying mechanisms of bevacizumab toxicities were included. RESULTS: Extensive experience with bevacizumab has proven the agent to be generally well tolerated, with an adverse event profile distinct from traditional cytotoxic chemotherapy and likely peculiar to its novel mechanism of action. The most common bevacizumab-attributable adverse event, hypertension, can be medically-managed, but more serious adverse events such as bowel perforation require drug discontinuation. CONCLUSIONS: Current best evidence supports the use of bevacizumab in selected patients, and safe administration of bevacizumab requires an understanding of the management of adverse events attributable to its use. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: The purpose of this review is to discuss the side effect profile of bevacizumab, to discuss proposed mechanisms of these toxicities, and to provide suggestions for management of adverse events. METHODS: A search of MEDLINE and ASCO and SGO abstract databases of articles published between January 1970 and August 2009 addressing the toxicity of bevacizumab in solid tumors was conducted. Reporting was limited to best available evidence including any available phase III studies and ovarian cancer phase II studies. Original publications addressing underlying mechanisms of bevacizumabtoxicities were included. RESULTS: Extensive experience with bevacizumab has proven the agent to be generally well tolerated, with an adverse event profile distinct from traditional cytotoxic chemotherapy and likely peculiar to its novel mechanism of action. The most common bevacizumab-attributable adverse event, hypertension, can be medically-managed, but more serious adverse events such as bowel perforation require drug discontinuation. CONCLUSIONS: Current best evidence supports the use of bevacizumab in selected patients, and safe administration of bevacizumab requires an understanding of the management of adverse events attributable to its use. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz Journal: J Surg Oncol Date: 2005-09-01 Impact factor: 3.454
Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Carol Aghajanian; Barbara Goff; Lawrence R Nycum; Yan V Wang; Amreen Husain; Stephanie V Blank Journal: Gynecol Oncol Date: 2015-08-10 Impact factor: 5.482
Authors: Yi Xie; Martin J Hicks; Stephen M Kaminsky; Malcolm A S Moore; Ronald G Crystal; Arash Rafii Journal: Gynecol Oncol Date: 2014-08-06 Impact factor: 5.482